A new trial reveals that weekly injections of the weight-loss drug Wegovy (semaglutide) lowered the risk of death from COVID-19 by about a third and reduced overall mortality by 19%. The study followed more than 17,000 participants with heart disease and obesity, showing that Wegovy decreased the likelihood of death from cardiovascular disease by 15% and other causes by 23%.
You May Also Like
Infrared Light Therapy Shows Promise for Brain Injury Recovery
October 14, 2024
Persistent Virus May Drive Long COVID
October 14, 2024
Liver Inflammation Linked to Cognitive Decline in Aging
October 13, 2024
More From Author
Humans Can Detect Quick Chemical Changes in Smells with Each Sniff
October 14, 2024
Human-Specific Genes Reveal Link Between Brain Growth and Autism
October 14, 2024
Infrared Light Therapy Shows Promise for Brain Injury Recovery
October 14, 2024
+ There are no comments
Add yours